Craig Hilts


Hilts, Craig

Craig Hilts is an experienced corporate lawyer who advises clients on capital markets transactions with a focus on initial public offerings. He also advises public companies on SEC reporting obligations and related corporate governance matters.

Over the course of his career, Mr. Hilts has played an integral role in advising issuers and investment banks on numerous SEC-registered equity and debt issuances, exchange and tender offers, and MTN- and structured-product programs. He has also advised on a variety of corporate governance issues for US-listed companies, shareholder proposals, proxy statements, and other public company reporting obligations under the Securities Exchange Act of 1934, including 10-K, 10-Q, 8-Ks, Section 16 reporting and beneficial ownership reporting.

Prior to joining WilmerHale, Mr. Hilts was a capital markets associate at Linklaters LLP in New York, where he primarily advised issuers on cross-border transactions. He was previously a corporate and finance associate in the New York office of Sullivan & Cromwell LLP where his representative transactions included debt and equity offerings for a variety of companies. In 2011, Mr. Hilts served as a secondee at Goldman Sachs & Co.

Community Activities

For several years, Mr. Hilts was a member of the Young Executive Board of a nonprofit organization dedicated to motivating young students in disadvantaged neighborhoods to become readers by bringing authors to participate in in-class discussions. Mr. Hilts completed the 2013 New York Marathon. 

Publications & News


December 11, 2017

WilmerHale Represents Editas Medicine in $50M Offering of Common Stock

Editas Medicine, Inc., a leading genome editing company, announced the pricing of an underwritten offering of 1,970,000 shares of its common stock.

November 14, 2017

WilmerHale Reps Apellis Pharmaceuticals in Initial Public Offering

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering.

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.


Skip Navigation Links.


JD, cum laude, Catholic University of America, Columbus School of Law, 2008, Editorial Assistant, Catholic University Law Review

BA, Economics and Political Science, Wake Forest University, 2003

Bar Admissions


New York

Skip Navigation Links.